Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications

We conducted an analysis across multiple PD-L1 combined positive score (CPS) indications to establish concordance of a 22C3 antibody–based laboratory-developed test (LDT) on the Ventana BenchMark XT or BenchMark ULTRA platform and the regulatory-approved PD-L1 IHC 22C3 pharmDx in cervical cancer (CC...

Descripción completa

Detalles Bibliográficos
Autores principales: Vainer, Gilad, Huang, Lingkang, Emancipator, Kenneth, Nuti, Shanthy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237432/
https://www.ncbi.nlm.nih.gov/pubmed/37267266
http://dx.doi.org/10.1371/journal.pone.0285764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237432/
https://www.ncbi.nlm.nih.gov/pubmed/37267266
http://dx.doi.org/10.1371/journal.pone.0285764

Ejemplares similares